Investment Analysts’ Weekly Ratings Changes for Cognition Therapeutics (CGTX)

by · The Markets Daily

A number of firms have modified their ratings and price targets on shares of Cognition Therapeutics (NASDAQ: CGTX) recently:

  • 12/8/2025 – Cognition Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 12/4/2025 – Cognition Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
  • 12/1/2025 – Cognition Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/24/2025 – Cognition Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/21/2025 – Cognition Therapeutics had its “buy” rating reaffirmed by analysts at B. Riley. They now have a $3.00 price target on the stock, up previously from $2.00.
  • 11/19/2025 – Cognition Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
  • 11/18/2025 – Cognition Therapeutics had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
  • 11/8/2025 – Cognition Therapeutics was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.

Featured Stories